Premier Alternatives

Merida Biosciences

Biotech · Cambridge, MA · Founded 2022 · Privately Held (backing)

Developer of targeted immunotherapies designed for the treatment of autoimmune and allergic diseases. Merida Biosciences is based in Cambridge, MA and was founded in 2022. It was valued at $228 million at its early-stage round in Apr 2025, the last priced event on record. It has raised $154 million across 1 recorded round; the latest was a $121 million Series A in Apr 2025.

PMV mark · valuation
$228.0M
Oct 2026
Priced at
its early-stage round
Apr 2025
Total raised
$154.0M
Last round
Series A
Apr 2025

Merida Biosciences key facts

as of Oct 2026
  • Developer of targeted immunotherapies designed for the treatment of autoimmune and allergic diseases.
  • Merida Biosciences is valued at approximately $228.0M as of Oct 2026, set at its early-stage round, Apr 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $154.0M across 1 recorded rounds; the latest was Series A ($121.0M) in Apr 2025.
  • Notable investors include GV, The Engine, Perceptive Advisors, Bain Capital Life Sciences, Third Rock Ventures — 6 tracked in total.
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$228.0M

Valued at $228.0M at its early-stage round, Apr 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Merida Biosciences with a free account
  • ·Everyone on the team, board and advisors included
  • ·Watch Merida Biosciences: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Merida Biosciences funding rounds

1 rounds
Apr 2025Series A$121.0M▮
Full funding history →

Merida Biosciences leadership

Merida Biosciences valuation

Merida Biosciences was valued at $228 million at its early-stage round in Apr 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Merida Biosciences raised?

Merida Biosciences has raised $154 million in total; 1 of its rounds is on record. The largest on record was a $121 million Series A in Apr 2025.

Merida Biosciences investors

6 investors are on record for Merida Biosciences, including GV, The Engine, Perceptive Advisors and Bain Capital Life Sciences.

Who runs Merida Biosciences

8 people are listed on the Merida Biosciences team: 6 executives and 2 advisors and observers, including Adam Townsend (President) and Dario Gutierrez (Founder).

Comparable companies

Comparable biotech names by valuation on PrivateMarketView: Chai Discovery ($1.3 billion), Nuwacell ($203 million) and InduPro ($125 million).

About Merida Biosciences

Developer of targeted immunotherapies designed for the treatment of autoimmune and allergic diseases. The company's platform focuses on the selective elimination of disease-causing antibody-producing cells while sparing healthy immune function, enabling healthcare providers to address underlying disease mechanisms more effectively.

Industry
Biotech
Sector
Healthcare
HQ
Cambridge, MA, United States
Founded
2022
Employees
45
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.